ArticleNature2020
Functional genomic landscape of cancer-intrinsic evasion of killing by T cells.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 301 papers.
0numbers the graph read from it
0cells of the map it votes in
301citing papers in PubMed
22.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
301 citing papers in PubMed, 461 citations in OpenAlex.
- Tumor cell-intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer.Science advances · 2026Article
- Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design.Molecular cancer · 2026Review
- High-Content CRISPR Screening: Methods and Applications.MedComm · 2026Review
- A blood-brain barrier-like vascular gate in neuroendocrine cancers opens new avenues for immunotherapy.Clinical and translational medicine · 2026Article
- DRIVE: a comprehensive resource deciphering drug-induced transcriptomic and splicing response in cancer cell.Neoplasia (New York, N.Y.) · 2026Article
- Autophagy modulation in cancer.Nature reviews. Drug discovery · 2026Review
- Genetic Ablation and Multi-Omics Profiling Reveal CEP55 as a Key Driver of Tumorigenesis in Diverse Cancer Models.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Genome-Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advancing targeted protein degradation: pLIRTAC's role in glioma and CAR-T cell therapy.Autophagy · 2026Article
- CARM1-mediated hypoxanthine-enriched exosomes rewire inosine metabolism and impair CD8Cell death and differentiation · 2026Article
- mTORC1 suppression by Trp53 mutation drives resistance to immune checkpoint blockade.Cell death & disease · 2026Article
- Pan-cancer 8q24 amplification predicts primary immunotherapy resistance and therapeutic vulnerabilities.iScience · 2026Article
- Innovative peptide-loaded hybrid membrane nanovaccine enables precise personalized immunotherapy for HPV-related cervical diseases.Signal transduction and targeted therapy · 2026Article
- Inflammatory cytokines induce new cancer dependencies.Nature genetics · 2026Article
- CR1(+) tumor-associated macrophages orchestrate an immunosuppressive niche in hepatocellular carcinoma: a genetic and multi-omics dissection.Journal of translational medicine · 2026Article
- Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapy.Journal for immunotherapy of cancer · 2026Article
- Tumour-associated high endothelial venules drive portal-specific immune evasion in lymph nodes via ALOX12.Nature communications · 2026Article
- CRISPR and compound screens in a novel ex vivo tissue model identify DDR1 and ETA as regulators of cancer cell invasion.Cellular & molecular biology letters · 2026Article
- Programmed cell death in lung cancer: mechanisms, immune responses, and therapeutics.Apoptosis : an international journal on programmed cell death · 2026Review
- Inducible, split base editors for in vivo cancer functional genomics.Nature biotechnology · 2026Article
241 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
43 authors at 6 institutions in 2 countries.
Keith A Lawson *Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Cristovão M Sousa *Agios Pharmaceuticals, Cambridge, MA, USA.
Xiaoyu ZhangDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Eiru KimDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1901-5670
Rummy AktharDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Joseph J CaumannsDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Yuxi YaoDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Nicholas MikolajewiczDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-7525-0384
Catherine RossDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Kevin R BrownDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-5514-2538
Abdelrahman Abou ZidDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Zi Peng FanAgios Pharmaceuticals, Cambridge, MA, USA.
Shirley HuiDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Jordan A KrallAgios Pharmaceuticals, Cambridge, MA, USA.
Donald M SimonsAgios Pharmaceuticals, Cambridge, MA, USA.
Chloe J SlaterAgios Pharmaceuticals, Cambridge, MA, USA.
Victor De JesusAgios Pharmaceuticals, Cambridge, MA, USA.
Lujia TangAgios Pharmaceuticals, Cambridge, MA, USA.
Richa SinghAgios Pharmaceuticals, Cambridge, MA, USA.
Joshua E GoldfordAgios Pharmaceuticals, Cambridge, MA, USA.
Sarah MartinAgios Pharmaceuticals, Cambridge, MA, USA.
Qian HuangDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Elizabeth A FrancisDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Andrea HabsidDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Ryan ClimieDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
David TieuDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Jiarun WeiDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Ren LiCell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.
Amy Hin Yan TongDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Michael AreggerDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0001-6443-9870
Katherine S ChanDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Hong HanDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Xiaowei WangDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Patricia MeroDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
John H BrumellDepartment of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-5802-7789
Antonio FinelliDivision of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Laurie AillesDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0001-7289-8882
Gary BaderDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0003-0185-8861
Gromoslaw A SmolenAgios Pharmaceuticals, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-0136-4685
Gillian A KingsburyAgios Pharmaceuticals, Cambridge, MA, USA.
Traver HartDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Charles KungAgios Pharmaceuticals, Cambridge, MA, USA.
Jason MoffatDonnelly Centre, University of Toronto, Toronto, Ontario, Canada. j.moffat@utoronto.ca.ORCID http://orcid.org/0000-0002-5663-8586
University of Toronto · CAAgios Pharmaceuticals (United States) · USThe University of Texas MD Anderson Cancer Center · USUniversity Health Network · CAHospital for Sick Children · CAOntario Institute for Cancer Research · CA
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MHigh-content microscopy platform for multiplex perturbation/multiplex readout studiesR35GM130119 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Traver Hart · 2018 to 2026
$3.9MNCI NIH HHS P30 CA016672NIGMS NIH HHS R35 GM130119
Abstract
The genetic circuits that allow cancer cells to evade destruction by the host immune system remain poorly understood
Indexed as
GenomicsAnimalsAutophagyCell Line, TumorFemaleGenes, NeoplasmGenomeHumansInterferon-gammaMaleMiceNeoplasmsNF-kappa BReproducibility of ResultsSignal TransductionT-Lymphocytes, CytotoxicInterferon-gammaNF-kappa B
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.